UCB (OTCMKTS:UCBJF) Shares Down 5.9% – Should You Sell?

UCB SA (OTCMKTS:UCBJF)’s share price traded down 5.9% during trading on Thursday . The stock traded as low as $248.60 and last traded at $248.60. 69 shares traded hands during trading, a decline of 90% from the average session volume of 725 shares. The stock had previously closed at $264.09.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on UCBJF shares. Piper Sandler restated a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Jefferies Financial Group upgraded shares of UCB to a “hold” rating in a report on Monday, August 3rd. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, UCB has an average rating of “Moderate Buy”.

UCB Stock Performance

The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The business has a fifty day moving average price of $276.22 and a 200-day moving average price of $291.65.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.